指南与共识慢性肾脏病肾血管病与高血压

糖尿病肾脏疾病患者高血压管理:英国临床糖尿病医师协会与英国肾脏协会(ABCD-UKKA)2021年联合指南摘要

Management of Hypertension in Patients With Diabetic Kidney Disease: Summary of the Joint Association of British Clinical Diabetologists and UK Kidney Association (ABCD-UKKA) Guideline 2021.
指南 / 共识 · Kidney Int Rep · 2022-01-13

该指南由英国临床糖尿病医师协会与英国肾脏协会联合制定,系统回顾糖尿病肾脏疾病(DKD)高血压管理证据,提出根据年龄、糖尿病类型和CKD分期个体化控制血压及选用降压药物的综合推荐。

要点

  • DKD占全球慢性肾脏病(CKD)病例的40%以上,高血压是DKD进展及心血管疾病和死亡的主要危险因素。
  • 肾素-血管紧张素阻断剂可减少1型和2型糖尿病患者的DKD进展和心血管事件,但获益随CKD分期而异。
  • 钠-葡萄糖协同转运蛋白2抑制剂、非甾体选择性盐皮质激素受体拮抗剂和内皮素A受体拮抗剂在延缓DKD进展和减少心血管事件方面有新证据。

核心结论

  • 该指南由糖尿病医师和肾脏科医师联合制定,基于现有证据提出根据年龄、糖尿病类型和CKD分期个体化控制血压及使用降压药物的综合推荐。

研究设计与样本

  • 该指南由英国临床糖尿病医师协会与英国肾脏协会联合制定,系统回顾了关于DKD高血压管理的所有现有证据。

主要发现

  • DKD占全球CKD病例的40%以上,高血压是DKD进展及高心血管疾病发病率和死亡率的主要危险因素。
  • 随机对照试验证据在1型和2型糖尿病及不同DKD分期中对目标血压存在差异。
  • 肾素-血管紧张素阻断剂可减少1型和2型糖尿病患者的DKD进展和心血管事件,但获益随CKD分期而异。
  • 钠-葡萄糖协同转运蛋白2抑制剂、非甾体选择性盐皮质激素受体拮抗剂和内皮素A受体拮抗剂在延缓DKD进展和减少心血管事件方面有新证据。

关键数值与推荐

  • 该指南根据年龄、糖尿病类型和CKD分期提出个体化血压控制及降压药物使用的推荐。

临床怎么用

  • 临床可依据该指南根据年龄、糖尿病类型和CKD分期个体化控制血压并选用降压药物。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Diabetic kidney disease (DKD) accounts for >40% cases of chronic kidney disease (CKD) globally. Hypertension is a major risk factor for progression of DKD and the high incidence of cardiovascular disease and mortality in these people. Meticulous management of hypertension is therefore crucial to slow down the progression of DKD and reduce cardiovascular risk. Randomized controlled trial evidence differs in type 1 and type 2 diabetes and in different stages of DKD in terms of target blood pressure (BP). Renin-angiotensin blocking agents reduce progression of DKD and cardiovascular events in both type 1 and type 2 diabetes, albeit differently according to the stage of CKD. There is emerging evidence for the benefit of sodium glucose cotransporter 2, nonsteroidal selective mineralocorticoid antagonists, and endothelin-A receptor antagonists in slowing progression and reducing cardiovascular events in DKD. This UK guideline, developed jointly by diabetologists and nephrologists, has reviewed all available current evidence regarding the management of hypertension in DKD to produce a set of comprehensive individualized recommendations for BP control and the use of antihypertensive agents according to age, type of diabetes, and stage of CKD (https://ukkidney.org/sites/renal.org/files/Management-of-hypertension-and-RAAS-blockade-in-adults-with-DKD.pdf). A succinct summary of the guideline, including an infographic, is presented here.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Banerjee D, Winocour P, Chowdhury TA, et al. Management of Hypertension in Patients With Diabetic Kidney Disease: Summary of the Joint Association of British Clinical Diabetologists and UK Kidney Association (ABCD-UKKA) Guideline 2021. Kidney Int Rep. 2022. PMID: 35497783. doi:10.1016/j.ekir.2022.01.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。